Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 19/20 | 0.67 |
| ▸ | CDK2 | P24941 | 19/20 | 0.67 |
| ▸ | CCND1 | P24385 | 16/20 | 0.67 |
| ▸ | CDK6 | Q00534 | 16/20 | 0.67 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.67 |
| ▸ | CDK9 | P50750 | 7/20 | 0.67 |
| ▸ | CDK4 | P11802 | 6/20 | 0.67 |
| ▸ | CCND3 | P30281 | 1/20 | 0.61 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672972 | 0.95 | CCNE1 (0.62) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL4766534 | 0.95 | CCNE1 (0.60) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3675736 | 0.95 | CCNE1 (0.60) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3669727 | 0.95 | CCNE1 (0.62) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3668200 | 0.95 | CCNE1 (0.62) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3674341 | 0.94 | CCNE1 (0.72) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL917525 | 0.93 | CCNE1 (0.59) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3680079 | 0.91 | CCNE1 (0.58) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3677235 | 0.91 | CCNE1 (0.59) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3673672 | 0.91 | CCNE1 (0.68) | CCNE1CDK2CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | claimed |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | disclosed |
| US-20100029728-A1 | PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-02-04 | — | — | US | disclosed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | disclosed |
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | disclosed |
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | RANBAXY LABORATORIES LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
| EP-1958947-A1 | Inhibitors of phosphodiesterase type 4 | Ranbaxy Laboratories Limited (IN) | 2008-08-20 | — | — | EP | disclosed |
| EP-1931667-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007036791-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | PDE4A, PDE4B, PDE4C | CCNE1 3442/4885CDK2 827/4885CCND1 3084/4885 |
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | PNPO, TPMT, NOD1 | CCNE1 863/4885CDK2 393/4885CCND1 539/4885 |
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | ADRB2, ADRB1, ADRA2C | CCNE1 4437/4885CDK2 1168/4885CCND1 4363/4885 |
| US-20100029728-A1 | PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE4C | CCNE1 3629/4885CDK2 967/4885CCND1 3106/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | CCNE1 4327/4885CDK2 944/4885CCND1 4075/4885 |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | PDE4A, PDE4B, PDE4C | CCNE1 2955/4885CDK2 912/4885CCND1 3051/4885 |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | CCNE1 4312/4885CDK2 936/4885CCND1 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.